Empowered Patient Podcast

Filippo Petti, CEO, Celyad discusses how the company is broadening precision medicine by developing CAR-T immunotherapies to express a natural killer receptor that can recognize and target multiple ligands expressed in up to 80% of all cancers. Filippo talks about the value to cancer patients of both personalized (autologous) and off the shelf (allogeneic) CAR-T therapies and CYAD-101, Celyad's allogeneic CAR-T therapy, that demonstrated for the first time ever, clinical effectiveness in solid tumors.

@CelyadSA

#CAR_T #NKCells #cancer #immunotherapy #CellTherapy #solidtumors #Tcell #CYAD101 #allogeneic $CYAD

Celyad.com

Listen to the podcast here

Sponsored by TREND.Community

Filippo Petti, CEO, Celyad discusses how the company is broadening precision medicine by developing CAR-T immunotherapies to express a natural killer receptor that can recognize and target multiple ligands expressed in up to 80% of all cancers. Filippo talks about the value to cancer patients of both personalized (autologous) and off the shelf (allogeneic) CAR-T therapies and CYAD-101, Celyad's allogeneic CAR-T therapy, that demonstrated for the first time ever, clinical effectiveness in solid tumors.

@CelyadSA

#CAR_T #NKCells #cancer #immunotherapy #CellTherapy #solidtumors #Tcell #CYAD101 #allogeneic $CYAD

Celyad.com

Download the transcript here

Nevan Elam, J.D. CEO and co-founder Rezolute, Inc. talks about their work developing therapeutics for congenital hyperinsulinism, a rare pediatric disease and for diabetic macular edema, a vision-related complication of diabetes. With a background of working with technology businesses, Nevan reflects on lessons learned and differences in drivers of innovation in the computer and biotech worlds.

@rezolutebio

#RareDisease #PediatricDisease #DME #DiabeticMacularEdema #Diabetes #hyperinsulinism

RezoluteBio.com

Listen to the podcast here

Sponsored by TREND.Community

Nevan Elam, J.D. CEO and co-founder Rezolute, Inc. talks about their work developing therapeutics for congenital hyperinsulinism, a rare pediatric disease and for diabetic macular edema, a vision-related complication of diabetes. With a background of working with technology businesses, Nevan reflects on lessons learned and differences in drivers of innovation in the computer and biotech worlds.

@rezolutebio

#RareDisease #PediatricDisease #DME #DiabeticMacularEdema #Diabetes #hyperinsulinism

RezoluteBio.com

Download the transcript here

Anat Cohen-Dayag PhD chief executive officer, Compugen discusses the current immune-oncology treatment landscape, with only 20-30% of patients responding to currently available treatments, and the missing link that she believes her company may have found to improve the success rate. Anat talks about how Compugen's computational discovery platform works to discover new drug targets for treating solid tumors and how lead candidate COM701 has shown encouraging early stage results to date.

#immuno-oncology #cancer. #colorectalcancer

Compugen

Listen to the podcast here

Anat Cohen-Dayag PhD chief executive officer, Compugen discusses the current immune-oncology treatment landscape, with only 20-30% of patients responding to currently available treatments, and the missing link that she believes her company may have found to improve the success rate. Anat talks about how Compugen's computational discovery platform works to discover new drug targets for treating solid tumors and how lead candidate COM701 has shown encouraging early stage results to date.

#immuno-oncology #cancer. #colorectalcancer

Compugen

Download the transcript here

Ronnie Andrews, CEO, Oncocyte discusses the company's mission to answer critical questions along the cancer care continuum through the use of their molecular tests for diagnosis and treatment of early stage lung cancer. Ronnie also talks about the changes in cancer care over the past 20 years and the potential these tests have to positively impact patients in the future.

@oncocyteLBX

#moleculardiagnostics #lungcancer #liquidbiopsy #earlydetection

Oncocyte.com

Listen to the podcast here

Ronnie Andrews, CEO, Oncocyte discusses the company's mission to answer critical questions along the cancer care continuum through the use of their molecular tests for diagnosis and treatment of early stage lung cancer. Ronnie also talks about the changes in cancer care over the past 20 years and the potential these tests have to positively impact patients in the future.

@oncocyteLBX

#moleculardiagnostics #lungcancer #liquidbiopsy #earlydetection

Oncocyte.com

Download the transcript here

Brad Younggren MD, Chief Medical Officer, 98point6 talks about what happens when a company fundamentally changes the way patients interact with doctors by providing 24/7 on-line access to medical professionals aided by the camera and attachments on mobile devices to further inform the diagnosis and treatment plan. With enthusiastic support from traditional primary care doctors, this new model of on-demand care is showing effectiveness for addressing emergency as well as chronic conditions.

@98point6inc

98point6.com

Listen to the podcast here

Brad Younggren MD, Chief Medical Officer, 98point6 talks about what happens when a company fundamentally changes the way patients interact with doctors by providing 24/7 on-line access to medical professionals aided by the camera and attachments on mobile devices to further inform the diagnosis and treatment plan. With enthusiastic support from traditional primary care doctors, this new model of on-demand care is showing effectiveness for addressing emergency as well as chronic conditions.

@98point6inc

98point6.com

Download the transcript here